Bladder preservation: Optimizing radiotherapy and integrated treatment strategies

BJU International

Volumn 102, Issue 9B, 2008, Pages 1345-1353

  Mak, Raymond H ^a   Zietman, Anthony L ^a   Heney, Niall M ^a   Kaufman, Donald S ^a   Shipley, William U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; CYSTOSCOPY; HUMAN; LEUKOPENIA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PATIENT SELECTION; PELVIC NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; FORECASTING; HUMANS; NEOPLASM INVASIVENESS; PATIENT SELECTION; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 54049112622     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07981.x     Document Type: Review

References (64)

1. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001 19 : 666 75
2. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003 21 : 690 6
3. Hautmann RE, Gschwend JE, de Petriconi RC, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006 176 : 486 92
4. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003 349 : 859 66
5. Bassi P, Pagano F, Pappagallo G et al. Neo-adjuvant M-VAC of invasive bladder cancer: the G.U.O.N.E: multicenter phase III trial. Eur Urol 1998 33 (Suppl. 142
6. Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987 138 : 1162 3
7. Henry K, Miller J, Mori M, Loening S, Fallon B. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 1988 140 : 964 7
8. Hall RR. Transurethral resection for transitional cell carcinoma. Probl Urol 1992 6 : 460 70
9. Hall RR, Robert JT, Marsh MM. Radical transurethral surgery in chemotherapy aiming at bladder preservation. In Splinter WE, Scher HI, Neoadjuvant Chemotherapy in Invasive Bladder Cancer. New York : Wiley Liss, 1990 : 169 74
10. De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995 36 : 183 8
11. Gospodarowicz MK, Hawkins NV, Rawlings GA et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989 142 : 1448 53
12. Jenkins BJ, Caulfield MJ, Fowler CG et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988 62 : 343 6
13. Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995 31 : 247 54
14. Shearer RJ, Chilvers CF, Bloom HJ, Bliss JM, Horwich A, Babiker A. Adjuvant chemotherapy in T3 carcinoma of the bladder: a prospective trial: preliminary report. Br J Urol 1988 62 : 558 64
15. Slack NH, Bross ID, Prout GR Jr. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 1977 9 : 393 405
16. Miller LS. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 1997 39 (Suppl. 973 80
17. Sell A, Jakobsen A, Nerstrom B, Sørensen BL, Steven K, Barlebo H. Treatment of advanced bladder cancer category T2, T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 1991 138 : 193 201
18. Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 1982 54 : 136 51
19. Shipley WU, Prout GR Einstein AB et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987 258 : 931 5
20. Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996 14 : 2901 7
21. Hall RR, Newling DW, Ramsden PD, Richards B, Robinson MR, Smith PH. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984 56 : 668 72
22. Prout GR Shipley WU, Kaufman DS et al. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol 1990 144 : 1128 34
23. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998 16 : 1298 301
24. Sternberg CN, Pansadoro V, Calabrò F et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003 97 : 1644 52
25. Tester W, Porter A, Asbell S et al. Combined modality program with possible organ preservation for invasive bladder carcinoma. Results of RTOG Protocol 85-12. Int J Radiat Oncol Biol Phys 1993 25 : 783 90
26. Eapen L, Stewart D, Danjoux C et al. Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol 1989 7 : 230 5
27. Eapen L, Stewart D, Collins J, Peterson R. Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 2004 172 : 1276 80
28. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993 329 : 1377 82
29. Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996 14 : 119 26
30. Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998 16 : 3576 83
31. Sengeløv L, von der Maase H, Lundbech F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle invasive bladder tumors. Acta Oncol 2002 41 : 447 56
32. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999 354 : 533 40
33. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005 48 : 202 5
34. Housset M, Maulard C, Chretien Y et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993 11 : 2150 7
35. Housset M, Dufour B, Maulard C. Concomitant 5-fluorouracil-cisplatin and bifractionated split course radiation therapy for invasive bladder cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 165, Part I of II (June 1 Supplement), 2005 4506
36. Kaufman DS, Winter KA, Shipley WU et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000 5 : 471 6
37. Horwich A, Dearnaley D, Huddart R et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 2005 75 : 34 43
38. Hagan MP, Winter KA, Kaufman DS et al. RTOG 97-06: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with cisplatin followed by adjuvant MCV chemotherapy. Int J Radiat Oncol Biol Phys 2001 57 : 665 72
39. Roth BJ. The role of paclitaxel in the therapy of bladder cancer. Semin Oncol 1995 22 (Suppl. 12 33 40
40. Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000 18 : 1058 61
41. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999 17 : 2876 81
42. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000 18 : 1921 7
43. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000 18 : 3068 77
44. Kaufman DS, Winter KA, Shipley WS et al. Muscle-invading bladder cancer, RTOG Protocol 99-06: initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. ASCO Meet Abstract 2005 23 : 4506
45. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000 18 : 3247 55
46. de Wit R. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 2003 97 (Suppl. 2120 6
47. Kent E, Sandler H, Montie J et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 2004 22 : 2540 5
48. Hussain SA, Stocken DD, Peake DR et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004 90 : 2106 11
49. Chakravarti A, Winter K, Wu CL et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005 62 : 309 17
50. Cowan RA, McBain CA, Ryder WD et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004 59 : 197 207
51. Pos F, Horenblas S, Dom P, Moonen L, Bartelink H. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 2005 61 : 678 86
52. Hata M, Miyanaga N, Tokuuye K et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys 2006 64 : 1371 9
53. Pos FJ, Hulshof M, Lebesque J et al. Adaptive radiotherapy for invasive bladder cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2006 64 : 862 8
54. Shimizu S, Shirato H, Kitamura K et al. Use of an implanted marker and real-time tracking of the marker for the positioning of prostate and bladder cancers. Int J Radiat Oncol Biol Phys 2000 48 : 1591 7
55. Shipley WU, Kaufman DS, Zehr E et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002 60 : 62 7
56. Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002 20 : 3061 71
57. Miyanaga N, Akaza H, Okumura T et al. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. Int J Urol 2000 7 : 41 8
58. Arias F, Domínguez MA, Martínez E et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 2000 47 : 373 8
59. Hussain M, Glass TR, Forman J et al. Combination cisplatin, 5-fluorouracil and radiation therapy in locally advanced unresectable or medically unfit bladder cancer patients. A Southwest Oncology Group study. J Urol 2001 165 : 56 60
60. Coen JJ, Zietman AL, Kaufman DS et al. Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-sparing approach. In Lerner SP, Schoenberg MP, Sternberg CN, Textbook of Bladder Cancer. Oxford, Taylor & Francis, 2006 : 569 77
61. Zietman AL, Sacco D, Skowronski U et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003 170 : 1772 6
62. Caffo O, Fellin G, Graffer U et al. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer 1996 78 : 1089 97
63. Henningsohn L, Steven K, Kallestrup EB et al. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 2002 168 : 168 74
64. Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 2002 62 : 215 25